Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
“I’m concerned the company won’t be able to generate sufficient funding to progress the platform to a point where license deals are forthcoming.”
We have strengthened our negotiating position with cash runaway, which will only get stronger as data emerges, we have also hired a commercial powerhouse in Dec to do deals, new and ongoing discussions are taking place as per the presentation yesterday. Everything is on the table suggests they will partner lead assets and pivot to developing more toxic warheads. I expect deals done at the end of the 2w period imo or even before as current data proves commercial proof of concept of platform. It’s clear a more commercial focus is being put into place. Not much point having a wonderful science platform if you can’t monetise it. Sentiment might be destroyed at the moment however AIM has a very short memory when greed is involved and funding won’t be a problem imo. We are dealing with Billion dollar drugs on approval, people get greedy.
Novartis pays PeptiDream $180M as radiopharma big bang continues.
I also think that the BoD will be strengthened in the not too distant future
Rory, have you seen Simon Bennett’s CV? Far more impressive than mine!
Is Rory not allowed to give an opinion ? Perhaps if you listened you might learn something
If you're not happy Rory, sell up.
It’s a positive step that AS has been shown the door, but the company is still in a highly precarious situation.
I’m concerned the company won’t be able to generate sufficient funding to progress the platform to a point where license deals are forthcoming. I think Back to that (almost comical, in hindsight) article from AS in a Sunday paper re UK institutions being incapable of/unwilling to invest in UK biotechs, I fail to see where the funding will come from. If another placing was to be successful, it’d be at such a low price that dilution would be monumental.
Biotechs are loss making businesses, they burn through cash rapidly; CC is talking about a pipeline now, rather than one or two priority products, and the cost to develop this pipeline will be huge. I can’t see where the funding for this development will come from. I’ve stated this before but licensing deals and buyouts aren’t as common as many people on here like to suggest.
I think the 25% ownership of Affyxell and potential IPO could be the saving grace here, but I don’t think timelines are in our favour. Divesting the Dx side of the business - which is loss making - won’t provide even remotely sufficient funding.
I’m struggling to see how big pharma or vulture funds don’t pick Precision up for pennies on the pound late next year or early the following year.
I don’t think CC has the commercial expertise, experience or ruthlessness required to prevent this. As far as I’m concerned, the number one risk here is now funding (thanks to AS’ misguided leadership), not the science - and we have a scientist at the helm, not a finance or business professional.
What more data do you think they will release? They give us continued updates on the patients still on trial...but is there something you don't think that they have released yet that they should?
@PL - yeeeehawww!
Green box and ignore the fantasist. He’s living in his nans basement desperately hoping the government will renew his PIP, so he can buy more tasty crayons
So what do you do Groot …respond. What a berk
NathanR999...it all depends what their Distribution agreement mix is...how much is stocking vs non-stocking and who invoices (Principal in the case of house sales). Distribution can be very
lucrative if set up correctly.
The large contracts can be shipped and invoiced by the Principal (house account) with a royalty/commission paid to the Distributor who services the account.
60 staff seems a lot though...
Will they not release all 3 week data before that ?
So 6 months then
Early fall? The yanks are here! Yeehaw! Roll on t’internet switch on time. NY prints on the way
After the 2QW trial ends, so likely late summer or early fall.
Ref original post.
Was meant to say Rerate
Not rebate.
Damn predictive text
I'm happy with Dx now we've got it, if (and whilst Tony is doing the sums we can't say for sure) it is cash generative. Tony reckons this will happen in H224. Selling it at a loss would compound the original M&A strategy error. If it's adding to the bottom line, keep it. Hopefully it'll generate enough cash to cover the HCI payments in cash.
Green box and ignore the fantasist. He’s living in his nans basement desperately hoping the government will renew his PIP, so he can buy more tasty crayons.
Oh and just to be a bit clearer... 'Likewise, if DX has any non-stocking deals where they receive a commission on sales this cannot be used either until the payment is made.' Many Principals issue monthly commission statements but pay quarterly for example and the monthly statements cannot be considered just the actual payment once received.
This is where Licencing/Commission/Royalty deals can form a bit of a grey area when it comes to Going Concern especially in the early days.
That 25% investment is also significant, that’s obviously worth a few quid as well.
Opps! sorry should read 'Likewise, if DX has any non-stocking deals where they receive a commission on sales this cannot be used either.'
BV...Going Concern as you know is an accounting term and usually means the auditors are happy the company is stable for the near future...usually for the next 12 months. However, when it comes to certain Incomes, they are not given so much weight or even not considered at all when it comes to going concern factors by the auditors especially commission /milestone payments. TX might know what's due but until it's received is cannot be used in the assessment. Likewise, if TX has any non-stocking deals where they receive a commission on sales this cannot be used either.
Even if TX does more Licencing deals and receives regular milestone payments or commissions/royalties etc these cannot be considered until received.
As has also been pointed out the Coris acquisition deal has skewed the CODB line but that is short term.
Personally, I'm not worried about the Going Concern stuff...it's all pretty standard for where Avacta is in their growth cycle and acquisition deals etc. The biggest risk to Avacta has always been the AVA6000 trial outcomes and right now (unless something devistating/unforeseen happens) we are in a much better place than we were just 12 months ago. The markets, however, are not fully convinced because they are 'sales/income' orientated. Now we need the backing of real long term specialised investors - such as the ones I have highlighted. They will give us more credibility and they will be the go between for new deals with Pharma by standing in our corner when it comes to negotiating or future contracts etc. All big Pharma have their Venture/Investment arms and they use this as a way of getting in with for them a nominal investment but for the likes of Avacta this is what will be needed for real Commercialisation and Shareholder value.
I know I've banged on about it but I do feel we are on the cusp of securing such investment if not already done so.
If something financially significant happens a company is obliged to tell it's shareholders but they don't have to give all the detail. They could have just said in the fundraise RNS that it had been taken up by new and old investors but no they told us specifically that a European Specialised Healthcare Fund was involved too...they don't have to name and say more...they just have to tell us. Now we need to know how significant...the silence is key.
No - just a tedious moron.
When do we expect release of all of phase 1 results ?
Yeah but I’m right 😉
This moron is even more tedious than wynbore - and that's saying something!? LoL